Asset Details
Do you wish to reserve the book?
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
Do you wish to request the book?
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
2002
Overview
Background Obesity enhances hemodynamic alterations that predispose to a subsequent increase in left ventricular (LV) wall stress leading to LV hypertrophy. In obese subjects, weight reduction regresses LV mass (LVM), regardless of blood pressure. Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss. Methods Outpatients (n = 184, age 18-65 y, body mass index ≥30 to <40 kg/m2) were randomly assigned to 6 months of once daily double-blind treatment with sibutramine 10 mg or 20 mg, or placebo. LV dimensions, status and function of the valves, weight loss, blood pressure, heart rate, and electrocardiogram were assessed. Results For end point data sets, the mean ± SD LVM index (LVM/height) changes were −3.0 ± 11.9 g/m for placebo (n = 56), −4.4 ± 10.7 g/m for sibutramine 10 mg (n = 61), and −4.3 ± 10.9 g/m for sibutramine 20 mg (n = 56). The reductions observed in the sibutramine groups were statistically significant compared with baseline (P <.01), but pairwise comparison results with placebo were not statistically significant. There was no difference in overall status of the cardiac valves. A statistically significant greater weight loss was found in patients on both doses of sibutramine compared with placebo (P <.001). No statistically significant differences between the groups were observed in respect to blood pressure and electrocardiographic intervals, but a statistically significant increase in pulse rate (7 beats/min) was noted for patients with sibutramine treatment. Conclusion A 6-month treatment with sibutramine does not affect ventricular dimensions, heart valves, and electrocardiogram variables. (Am Heart J 2002;144:508-15.)
Publisher
Elsevier Inc,Elsevier,Elsevier Limited
Subject
/ Adult
/ Aged
/ Appetite Depressants - pharmacology
/ Appetite Depressants - therapeutic use
/ Biological and medical sciences
/ Blood Pressure - drug effects
/ Cyclobutanes - therapeutic use
/ Drug toxicity and drugs side effects treatment
/ Echocardiography - drug effects
/ Electrocardiography - drug effects
/ Female
/ Heart Valves - anatomy & histology
/ Heart Ventricles - anatomy & histology
/ Heart Ventricles - drug effects
/ Humans
/ Male
/ Obesity
/ Pharmacology. Drug treatments
/ Placebos
/ Pulse - statistics & numerical data
